MMC, VICC & TSU: Partners in Eliminating Cancer Disparities ( 1 of 3)
MMC、VICC
基本信息
- 批准号:8534727
- 负责人:
- 金额:$ 111.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-26 至 2016-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdvanced Malignant NeoplasmAdvisory CommitteesAfrican AmericanAgeAwardBiologyBiometryBreastCancer BurdenCancer CenterCancer Research InfrastructureChemistryClinicalClinical SciencesClinical TrialsCollaborationsColorectalCommitCommunitiesCommunity HealthcareCommunity OutreachComprehensive Cancer CenterConsensusCore FacilityDevelopmentDiagnosisDisciplineDiscipline of NursingDoctor of PhilosophyEducationEducational workshopEffectivenessEnvironmentEpidemiologyFacultyFundingGoalsHistopathologyHuman ResourcesIncidenceInstitutionJointsLeadLeadershipMalignant NeoplasmsMalignant neoplasm of lungMeasurableMinorityMinority-Serving InstitutionMissionMonitorNanotechnologyNational Cancer InstituteOutcomeParticipantPhasePilot ProjectsPopulationPositioning AttributePrevention strategyPrimary PreventionProstateRecruitment ActivityRelative (related person)ResearchResearch InfrastructureResearch PersonnelResearch TrainingResourcesScienceScientistServicesStrategic PlanningTargeted ResearchTennesseeTrainingTraining ProgramsTranslational ResearchTriad Acrylic ResinUnderrepresented MinorityUnited StatesUniversitiesWorkanticancer researchbasecancer educationcancer health disparitycancer therapycancer typecareer developmentdesigngraduate studenthealth disparityimprovedmedical schoolsmembermortalitymultidisciplinaryoutreachpopulation basedprogramsresearch and developmentsuccessundergraduate student
项目摘要
DESCRIPTION (provided by applicant): Strong ties have developed between cancer researchers at Meharry Medical College (MMC), Tennessee State University (TSU) and Vanderbilt-lngram Cancer Center (VICC) resulting in this formal Cancer Partnership. Our Partnership is dedicated to enhancing the strengths and eliminating the weaknesses of our three institutions as we move toward our shared goal of eliminating cancer disparities in the US. The U54 award is the bedrock of this collaboration and has moved our collaborative research more forcefully toward a relationship that is based on reciprocity and stronger mutual benefit. The overall objectives of this competing renewal application are: (1) to increase and stabilize the competitive cancer research capability of MMC and TSU; (2) to create stable, long-term collaborative relationships between MMC, TSU and the VICC in cancer research, research training, career development and cancer outreach; and (3) to improve the effectiveness of VICC research, training, career development, cancer education and cancer outreach activities specifically designed to benefit minority populations in the region served by VICC. Funds provided by this U54 will solidify our collaboration. During this phase of our Cancer Partnership, we continue to concentrate on amassing sufficient infrastructure for cancer research that will strengthen reciprocity between MMC, TSU and VICC. In addition to funding two full projects and two pilot studies involving collaborators from all three institutions, funds will be used to recruit investigators to TSU and VICC and to strengthen infrastructure in basic, epidemiologic and clinical cancer research through the support of core facilities providing expertise in biostatistics, clinical trial accruals, histopathology and cancer outreach. All activities involve coordinated, well-planned interactions between MMC, TSU and VICC and will be monitored by an Internal Advisory Committee composed of members from each institution and a Program Steering Committee composed of external, nationally-recognized cancer investigators and representation from the National Cancer Institute. A sustained and comprehensive Cancer Partnership is of immense benefit to the three participating institutions as well as the mid-South region of the US. The institution's complementary strengths will help the Cancer Partnership establish effective cancer research and increase training opportunities at two minority-serving institutions enhance community- and population-based science research targeting minority cancer-related disparities and increase training of minority scientists at an NCI-funded Comprehensive Cancer Center.
描述(由申请人提供):梅哈里医学院 (MMC)、田纳西州立大学 (TSU) 和范德比尔特-英格拉姆癌症中心 (VICC) 的癌症研究人员之间建立了牢固的联系,从而形成了正式的癌症合作伙伴关系。我们的合作伙伴关系致力于增强我们三个机构的优势并消除其弱点,以实现消除美国癌症差异的共同目标。 U54 奖项是此次合作的基石,使我们的合作研究更有力地走向基于互惠和更强互惠互利的关系。此次竞争性更新申请的总体目标是:(1)增强并稳定MMC和TSU的癌症研究竞争能力; (2) 在 MMC、TSU 和 VICC 之间在癌症研究、研究培训、职业发展和癌症外展方面建立稳定、长期的合作关系; (3) 提高 VICC 研究、培训、职业发展、癌症教育和癌症外展活动的有效性,这些活动专门旨在造福 VICC 服务地区的少数群体。 U54 提供的资金将巩固我们的合作。在我们癌症合作伙伴关系的这一阶段,我们继续专注于为癌症研究积累足够的基础设施,这将加强 MMC、TSU 和 VICC 之间的互惠关系。除了资助两个完整项目和两项涉及所有三个机构合作者的试点研究外,资金还将用于为 TSU 和 VICC 招募研究人员,并通过提供专业知识的核心设施的支持,加强基础、流行病学和临床癌症研究的基础设施。生物统计学、临床试验应计、组织病理学和癌症外展。所有活动都涉及 MMC、TSU 和 VICC 之间协调一致、精心策划的互动,并将由每个机构的成员组成的内部咨询委员会和由外部、国家认可的癌症研究人员和国家癌症中心代表组成的项目指导委员会监督研究所。持续、全面的癌症合作伙伴关系对于三个参与机构以及美国中南部地区都具有巨大的好处。该机构的互补优势将帮助癌症伙伴关系建立有效的癌症研究,并增加两个为少数族裔服务的机构的培训机会,加强针对少数族裔癌症相关差异的社区和人口科学研究,并在国家癌症研究所资助的综合中心增加对少数族裔科学家的培训。癌症中心。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Samuel Evans Adunyah其他文献
Samuel Evans Adunyah的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Samuel Evans Adunyah', 18)}}的其他基金
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities (1 of 3)
MMC、VICC
- 批准号:
9356457 - 财政年份:2011
- 资助金额:
$ 111.35万 - 项目类别:
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities (1 of 3)
MMC、VICC
- 批准号:
10012757 - 财政年份:2011
- 资助金额:
$ 111.35万 - 项目类别:
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities (1 of 3)
MMC、VICC
- 批准号:
9211638 - 财政年份:2011
- 资助金额:
$ 111.35万 - 项目类别:
1/3) MMC, VICC, and TSU: Partners in Eliminating Cancer Disparities
1/3) MMC、VICC 和 TSU:消除癌症差异的合作伙伴
- 批准号:
10493417 - 财政年份:2011
- 资助金额:
$ 111.35万 - 项目类别:
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities (1 of 3)
MMC、VICC
- 批准号:
9765041 - 财政年份:2011
- 资助金额:
$ 111.35万 - 项目类别:
1/3) MMC, VICC, and TSU: Partners in Eliminating Cancer Disparities
1/3) MMC、VICC 和 TSU:消除癌症差异的合作伙伴
- 批准号:
10705089 - 财政年份:2011
- 资助金额:
$ 111.35万 - 项目类别:
相似海外基金
BCM-TSU CURED Administration Core (AC)
BCM-TSU CURED 管理核心 (AC)
- 批准号:
10762266 - 财政年份:2023
- 资助金额:
$ 111.35万 - 项目类别:
BCM/TSU P20 Collaborative Union for Cancer Research, Education and Disparities (CURED) Administrative Core (AC)
BCM/TSU P20 癌症研究、教育和差异合作联盟 (CURED) 行政核心 (AC)
- 批准号:
10762046 - 财政年份:2023
- 资助金额:
$ 111.35万 - 项目类别:
Therapeutic targeting of RTK protein granules in cancer
RTK 蛋白颗粒在癌症中的治疗靶向
- 批准号:
10591331 - 财政年份:2023
- 资助金额:
$ 111.35万 - 项目类别: